Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bunamiodyl
- Development stage
- Discontinued
- Lead developer
- Guerbet
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Bunamiodyl is an iodinated organic compound formerly used as an oral radiopaque contrast medium for cholecystography and cholangiography. It functions by being absorbed from the gastrointestinal tract and excreted into the bile, allowing for X-ray visualization of the gallbladder and biliary ducts. However, its use was largely discontinued in the mid-1960s due to reports of severe nephrotoxicity, including fatal acute renal failure (anuria), particularly in patients with pre-existing hepatic impairment or when administered in high doses. Mechanistically, it competes with bilirubin and other organic anions for binding to hepatic cytoplasmic proteins (specifically the Z fraction), which can lead to transient hyperbilirubinemia.
- Brand names
- OrabilexOrabilix
- Other names
- bunamiodyl sodiumbunamiodylate sodium
Beyond the preview
Go deeper on bunamiodyl.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bunamiodyl.